Stocks · News reference

Can-Fite BioPharma Says Blinded Overall Survival In Pivotal Phase 3 Namodenoson Liver Cancer Study Appears Longer Than Originally Anticipated; Evaluating Earlier Timing For Planned Interim Analysis

Sep 8, 2026, 12:22 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 8, 2026, 12:30 PMBenzinga Newsdesk
Can Fite Biofarma H1 EPS $(1.24) Beats $(1.43) Estimate, Sales $202.000K, Same YoY
Can Fite Biofarma (AMEX:CANF) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.43) by 13.29 percent. This is a 71.1 percent increase over losses of $(4.29) per share from
CANF
BenzingaSep 2, 2026, 3:48 PMVandana Singh
Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
Can-Fite BioPharma reports longer survival in its Phase 3 liver cancer trial and raises $4 million through a warrant exercise.
CANF
BenzingaSep 2, 2026, 2:31 PMBenzinga Newsdesk
Can-Fite BioPharma shares are trading lower after the company said blinded overall survival in its Phase III Namodenoson study for advanced HCC appears longer than expected under the trial design assumptions.
CANF